BiliSeq Molecular Test Doubles Bile Duct Cancer Detection Sensitivity in University of Pittsburgh Study

University of Pittsburgh researchers develop BiliSeq, a molecular test that detects 82% of bile duct cancers, doubling the sensitivity of standard pathology.

By: AXL Media

Published: Mar 28, 2026, 11:10 AM EDT

Source: Information for this report was sourced from University of Pittsburgh

Solving the Diagnostic Dilemma of "Narrow Ducts"

Bile duct cancer (cholangiocarcinoma) is notoriously difficult to diagnose because tumors are often small, hard to reach, and obscured by inflammation or scar tissue. For decades, physicians have struggled with "false negative" biopsies, where traditional microscopic examination fails to find cancer cells even when a malignancy is present. This uncertainty often leads to repeated invasive testing or delayed surgeries. To address this, the University of Pittsburgh team developed BiliSeq, a next-generation sequencing test designed to spot the molecular "fingerprints" of cancer even when visible tumor cells are sparse or damaged.

Doubling the Sensitivity of Standard Care

In a massive real-world study published in Gastroenterology, BiliSeq was tested on nearly 3,000 specimens from patients across the U.S. The results were transformative:

Standard Pathology Sensitivity: 44%

BiliSeq Sensitivity: 82%